UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
In 2014, only 10 of the nation’s 132 pharmacy schools achieved a 100 percent pass rate on first-time attempts at the North American Pharmacist Licensure Examination (NAPLEX). The University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences was one of them, passing all 54 students who took the exam for the first time.
UC San Diego is ranked the 14th best university in the world for the third consecutive year, according to the 2015 Academic Ranking of World Universities (ARWU). The rankings were recently released by the Center for World-Class Universities at Shanghai Jiao Tong University, a public research university located in Shanghai, China, renowned as one of the oldest and most prestigious and selective universities in China. In addition, UC San Diego’s programs in life sciences, engineering, computer science, chemistry, and economics are ranked among the top 20 in the world. Nationally, UC San Diego is listed as the 12th best university.
The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), has awarded James McKerrow, MD, PhD, dean of the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, with a 2015 New Therapeutic Uses Award.
Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report that the common antibiotic azithromycin kills many multidrug-resistant bacteria very effectively — when tested under conditions that closely resemble the human body and its natural antimicrobial factors. The researchers believe the finding, published June 10 by EBioMedicine, could prompt an immediate review of the current standard of care for patients with certain so-called “superbug” infections.
With the threat of multidrug-resistant bacterial pathogens growing, new ideas to treat infections are sorely needed. Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report preliminary success testing an entirely novel approach — tagging bacteria with a molecular “homing beacon” that attracts pre-existing antibodies to attack the pathogens.
Urinary tract infections (UTIs) are common, and widespread antibiotic resistance has led to urgent calls for new ways to combat them. Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report that an experimental drug that stabilizes a protein called HIF-1alpha protects human bladder cells and mice against a major UTI pathogen. The drug might eventually provide a therapeutic alternative or complement to standard antibiotic treatment.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
